Editor

As Humira (adalimiumab) goes, so goes AbbVie. And it may require quite a few new products to replace the rheumatoid arthritis giant, which earned...

Dive Insight: Biogen took the most severe blow in its history last month, losing more than $20 billion in market capitalization on the announcement that...

TherapeuticsMD decided against diluting its shareholders again in order to get Bijuva (estradiol and progesterone) and Annovera (segesterone acetate and ethinyl estradiol) off the...

Pharma's recent slump in R&D productivity — the rate of success in relation to the time and effort invested in drug development — has...

CAR-T therapies represent a significant clinical advance for patients with certain types of advanced lymphoma. In clinical testing, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)...

By most measures, Novartis enjoyed a positive start to 2019. Drug sales rose by 5% in dollar terms, lifted by strong performances from the Swiss...

Deloitte's annual report on R&D productivity, while limited in scope, is an indicator of the challenges faced by large pharmaceutical firms in bringing new...

Alzheimer's drug development is notoriously difficult, exemplified by the fact there are no therapies approved to treat the underlying disease. That's not for a lack...

Biologics have been a business boon to contract manufacturers, Catalent included. Large-molecule drugs are such a focus, in fact, that last year Catalent split its...

Known for its work in the field of messenger RNA therapeutics, BioNTech is looking for new ways to grow. Earlier this month, the private...